HemoNatura product with natural botanical ingredients
Patented Botanical Formula

The first natural cream
that doesn't just relieve —
it restores.

Patent-protected. Peer-reviewed. 70,000–100,000 patients treated over four decades. 85%+ natural ingredients. Zero drug actives. Pure botanical science.

U.S. Patent — US8834944B2 · Filed & prosecuted by Diehl & Partner, Munich EU Patent — EP2022504B1 NIH / PubMed — PMID 24032710 FDA Medical Device — 510(k) Pathway
100K+
Patients treated
85%
Clinical success rate
40 yrs
Track record
$1.2B
U.S. market size
HemoNatura cream with natural botanical ingredients including horse chestnut and flowers
About HemoNatura™

Nature's answer to a condition that affects 75% of adults.

Existing OTC products mask symptoms with steroids, anesthetics, and vasoconstrictors. HemoNatura™ takes a different path — a 75%+ active botanical content formula with zero drug actives, whose primary mode of action is physical and mechanical, qualifying it as an FDA Medical Device under the 510(k) pathway.

Developed over four decades by Pharmacist Sait Küçükay and scaled for industrial production by Dr. Feyyaz Küçükay, the formula is protected by active patents in both the United States and Europe.

Explore Licensing ↗
The Scientists Behind the Formula

Six decades of scientific legacy.

HemoNatura™ is not a startup product. It is the culmination of three generations of scientific work — from a hospital laboratory in 1960s Istanbul to a globally patented formula today.

1950–1960 — Formulation
1960–2000s — Pharmacy Practice
2007–Today — Industrial Scale
🔬
The Chemist · 1960s

Şakir Üster

Organic Chemist · Hıfzıssıhha Baş Kimyageri · İstanbul İtfaiyesi · In Memoriam (2016)

Organic chemist and laboratory expert at Vakıf Gureba Hastanesi (today Bezmiâlem Vakıf Üniversitesi Hastanesi), one of Istanbul's most distinguished medical institutions. A graduate of İstanbul Üniversitesi Kimya Fakültesi, he built his career at the intersection of organic chemistry, biochemical analysis and applied pharmacology. Active member of the hospital's Mütehassıslar Heyeti (Scientific Expert Board) during the 1960s.

Specialised in toxicology, metabolic disease analysis, and blood/urine chemistry
Co-presented clinical cases in 160+ scientific presentations at the hospital's academic gatherings
Contributed analytical data to hospital bulletins alongside physicians Tuğrul Kâmil, Rasim Ulunay and Münir Eren
Applied his organic chemistry expertise to the extraction and synergistic formulation of botanical actives — the scientific core of the patent
Served as Chief Chemist at Hıfzıssıhha Enstitüsü (Turkey's national public health institute) — responsible for chemical safety analysis at a national level
Later served with İstanbul İtfaiyesi (Istanbul Fire Service), playing a leading role in extinguishing nearly 10 fires — applying his chemistry expertise to hazardous material incidents
Education & Career
İstanbul Üniversitesi, Kimya Fakültesi
Specialisation: Organic Chemistry
Hıfzıssıhha Enstitüsü — Baş Kimyager
Vakıf Gureba Hastanesi — Lab. Uzmanı
İstanbul İtfaiyesi — Kimya Uzmanı
⚗️
The Pharmacist · 1960s–2000s

Sait Küçükay

Military Pharmacist · Botanist · Büyük Barbaros Eczanesi · Est. 1954

Graduated from Askeri Tıbbiye (Military Medical Academy) as a military pharmacist between 1940–1950 — during the years when Jewish refugee professors fleeing Nazi Germany (Heilbronn, Rosentaller, Dukenuar) were teaching at İstanbul Üniversitesi and reshaping Turkish pharmacy and botanical science. Sait Küçükay absorbed this knowledge deeply: he was both a pharmacist and a botanist, skilled in extracting and preparing plant-based medicines. After a medical discharge from military service, he co-founded SAYKAN İlaç Üretim Laboratuvarı with his physician brother Dr. Hüseyin Küçükay — conducting both contract manufacturing and his own R&D into botanical preparations. Post-war economic hardship forced the laboratory to close. In 1954 he opened Büyük Barbaros Eczanesi in Nişantaşı, converting a large section of the pharmacy into a working laboratory. The vast majority of his preparations were botanical — majezik formulations he had refined over years. It was here, in collaboration with his brother-in-law the organic chemist Şakir Üster, that the hemorrhoid cream was perfected and given its name: HEMORRA-H.

Trained as military pharmacist at Askeri Tıbbiye; studied under German-Jewish refugee professors who transformed Turkish pharmacy science
Co-founded SAYKAN İlaç Üretim Laboratuvarı with Dr. Hüseyin Küçükay — early contract pharma manufacturing and botanical R&D
Opened Büyük Barbaros Eczanesi in 1954; converted its large interior into a working pharmaceutical laboratory
From 1960: produced HEMORRA-H by hand — mortar and pestle — for over 40 years; the vast majority of his preparations were botanical
Featured in Hürriyet's Güzin Abla column (1998) — patients avoided surgery thanks to his preparation; systematically archived thousands of patient letters
Pharmacy
Askeri Tıbbiye · SAYKAN İlaç Lab.
Büyük Barbaros Eczanesi
Nişantaşı, Istanbul · Est. 1954
HEMORRA-H production: 1960–2000s
🏭
Industrial Completion · 2007–Today

Feyyaz Küçükay

Inventor of Record · Patent Holder

Son of Sait Küçükay and nephew of Şakir Üster. Recognised that the magistral formula had never been formally documented or patented, and dedicated years to completing what the founders had begun.

Completed the missing scientific documentation and formal patent applications (EU: EP2022504B1 · US: US8834944B2 · Filed & prosecuted by Diehl & Partner, Munich)
Brought the magistral preparation to industrial-scale modern formulation under OFK İlaç
Coordinated the peer-reviewed clinical study (PMID: 24032710) and Prof. Dr. Tortum's independent clinical report
Presented the formula at international scientific congresses under the HEMORRA-H brand
Company
OFK İlaç
Üsküdar, Istanbul

"A formula conceived in a hospital laboratory in 1950, refined in a pharmacy from 1960, and now — six decades later — ready for the world."

Şakir Üster · Sait Küçükay · Feyyaz Küçükay — Three generations, one legacy.
The Formula

Four plants. One patented synergy.

Each ingredient is documented in peer-reviewed literature. Together they form a synergistic complex that no competitor has replicated.

01
Fig Leaves
Ficus carica
Anti-inflammatory action, supports tissue repair and vascular integrity at the application site
02
Horse Chestnut
Aesculus hippocastanum
Vascular toning, anti-edema — clinically documented in hemorrhoid management literature
03
Artichoke Leaves
Cynara scolymus
Antioxidant barrier, liver-supportive detox activity, protective mucosal reinforcement
04
Walnut Shells
Juglans regia
Astringent tissue support, antimicrobial protection, mechanical barrier reinforcement
One Formula. Four Categories.

Beyond hemorrhoids: a platform opportunity.

The patented base formula is not limited to a single indication. Minor reformulations yield four distinct product categories — applications (2), (3) and (4) were reported spontaneously by users, without any prompting from the inventor.

🎯
01 · Primary Use
Hemorrhoid
Cream
Patented. Peer-reviewed. 75-year heritage. US $1.2B market.
PATENTED
🦴
02 · User-Reported
Joint Pain
Relief
Anti-inflammatory actives (horse chestnut, fig leaf) show measurable efficacy for joint discomfort and reduced mobility.
🩹
03 · User-Reported
Wound
Care
Astringent and antimicrobial properties of walnut shell and artichoke support tissue repair and wound recovery.
💋
04 · User-Reported
Cold Sore
Treatment
Antiviral botanical actives (fig leaf, walnut shell) reported effective on labial herpes by users without prompting.
💡
Investor Implication
You are licensing one patented formula with four potential product lines. Minor reformulations extend into adjacent OTC categories — joint care, wound care, and antiviral — each worth hundreds of millions. This is a platform asset, not a single-SKU acquisition.
Clinical Evidence

Two independent validation streams.

Pre-clinical science backed by a peer-reviewed NIH-indexed publication, and four decades of real-world outcomes — with documentation.

Pre-clinical study
Wistar rat model with croton-oil induced hemorrhoids. Histological, immunohistochemical and biochemical markers confirmed. Full formula showed greatest tissue recovery of all test groups.
Published · Chin J Physiol · PMID 24032710
1,800-patient clinical trial
Independent professor-led study. Documented healing outcomes across all four hemorrhoid grades. 85% success rate. Full clinical report available to qualified partners under NDA.
All 4 grades · 85% success · NDA available
100,000+ real-world patients
Four decades of magistral dispensing by Pharmacist Sait Küçükay. Field application by Dr. Feyyaz Küçükay. Evidence on file: patient messages, press documentation, and records — available at meeting.
40 years · Documentation available
Toxicity profile
Murine toxicity studies completed. Safe profile confirmed across all four botanical extracts. No adverse effects identified. Independent safety documentation available in published literature.
Murine studies complete · No adverse effects
Prof. Dr. Osman Tortum clinical report — Cerrahpaşa Medical Faculty
Independent Clinical Report

Signed report by Prof. Dr. Osman Tortum

General Surgery Specialist, Cerrahpaşa Medical Faculty — University of Istanbul. The report documents 412 patient applications of the formula between January 2008 and April 2010, noting observed outcomes in bleeding cessation, reduction of hemorrhoidal tissue, and overall efficacy.

412
Patients documented in report
~85%
Observed success rate
"Elde edilen başarı oranı takriben %85 civarında görülmektedir."
— Prof. Dr. Osman B. Tortum · Cerrahpaşa Tıp Fakültesi · 19.04.2010
Competitive Landscape

What no competitor offers.

Feature HemoNatura™
Preparation H variants Anusol / Tucks variants
No steroids or synthetic chemicalsRapid Relief
(Haleon)
Anusol HC
(C&D)
Tucks Pads
(Medline)
Natural
(various)
Clinically documented tissue recovery support
85%+ natural ingredients, zero drug actives
Patented botanical formula (US + EU)
Independent NIH-indexed clinical study
Qualifies for FDA Medical Device 510(k) pathway
No steroids or synthetic chemicals✗ Phenylephrine✗ Lidocaine✗ Hydrocortisone
Clinically documented tissue recovery support
Intellectual Property

Protected in two continents.

The complete IP package — patents, formula, clinical data, manufacturing method — is available for licensing or acquisition.

🇺🇸
U.S. Patent
US8834944B2 · Filed & prosecuted by Diehl & Partner, Munich
ACTIVE
PCT extension of EP patent. Full U.S. market protection. Formulation updates enable patent continuity beyond current term.
🇪🇺
European Patent
EP2022504B1
GRANTED & ACTIVE
Filed August 2007. Granted October 2012. Covers formula and method of manufacture across EU member states.
📄
Peer-Reviewed Publication
PMID 24032710
NIH / PUBMED INDEXED
Chinese Journal of Physiology, 2013. Authors: Gurel E. et al., Istanbul University. Validates the formula's mechanism of action.
Documented Outcomes

Four decades of documented outcomes.

From national press coverage to personal patient letters — the formula has left a documented trail across four decades. A selection is shown below; the full archive is available at qualified partner meetings.

NATIONAL PRESS
Hürriyet Gazetesi
Güzin Abla Köşesi · 14 Mayıs 1998
View Original Article
Hürriyet Gazetesi Güzin Abla köşesi - HemoNatura press coverage
Newspaper clippings documenting patient outcomes

"Nişantaşı'ndaki o eczacı bey, kendi hazırladığı bitkisel bir ilaç sayesinde hemoroid hastalığını tedavi ediyordu. Bu arada ilacı kullanan hastalardan gelen şükran mektuplarını da düzenli olarak dosyalıyor ve bununla gurur duyuyordu."

In one of Turkey's most widely-read newspaper columns, Güzin Abla recounted how a reader had been facing hemorrhoid surgery — and avoided it entirely after using Pharmacist Sait Küçükay's botanical cream. The columnist noted that the pharmacist had been systematically filing letters of gratitude from patients, and that many of her own readers had benefited from the formula. The article generated such demand that she republished the pharmacy's contact details.

Hemorra-H congress exhibition stand with patents and scientific studies display
SCIENTIFIC CONGRESS

OFK İlaç Exhibition Stand

The formula was formally presented at an international scientific congress under the OFK İlaç brand. The exhibition stand featured three dedicated panels: Patents (Patentlerimiz), the Product (Hemorra-H Onarıcı Bakım Kremi), and Scientific Studies (Bilimsel Çalışmalar) — including the peer-reviewed publication, microbiology, and stability data.

Patent portfolio displayed Peer-reviewed publication Microbiology & stability data 75% botanical content
Handwritten patient letters documenting outcomes over 40 years
Archive
A selection of patient correspondence filed by Pharmacist Sait Küçükay — spanning four decades of documented outcomes.
★★★★★

"Doktorlarım ameliyat önerdi. Sait Bey'in kremini kullandıktan sonra ameliyata gerek kalmadı. Bu ilacı herkese tavsiye ediyorum."

S.M.
S.M.
Patient letter · Istanbul · 1997
★★★★★

"Yıllarca çeşitli ilaçlar denedim. Bu krem hem doğal hem de gerçekten işe yarayan tek ürün oldu. Yan etkisi yok, sonucu var."

H.Y.
H.Y.
Patient letter · Ankara · 2003
★★★★★

"Tamamen bitkisel olması beni en çok etkileyen özelliği. Üç hafta kullandıktan sonra fark belirgin oldu. Ailemin birkaç üyesine de önerdim."

F.K.
F.K.
Patient letter · Izmir · 2008

Patient initials are used to protect privacy. Original letters, press cuttings, and documented records are available for review at qualified partner meetings. Individual results may vary. HemoNatura™ is currently offered for licensing or acquisition and is not yet approved for sale in the United States.

For Partners & Investors

A deal-ready IP package for the right partner.

We are seeking a licensing or acquisition partner to bring HemoNatura™ to the U.S. market. Three deal structures are available — all with full IP documentation ready under NDA.

Exclusive License (Preferred)Upfront technology transfer fee + royalty on net sales (up to 8%). Change of control protection clauses included.
Full IP AcquisitionOutright sale of U.S. + EU patents, formula, clinical data package, and brand assets.
Joint VentureCo-development model with equity stake for IP contribution and shared FDA pathway costs.
Request Access

Investor deck & clinical report

Full documentation — patents, clinical data, milestone schedule, and licensing terms — available to qualified partners under NDA.

Confidential · NDA required · contact@hemonatura.com